Baxter's Vepacel flu vaccine approved in Europe; Medicago and Mitsubishi Tanabe hook up for vaccine R&D deal;

> Baxter has received marketing approval in Europe for its inactivated adult influenza vaccine, Vepacel. Press release

> Bavarian Nordic has submitted its smallpox vaccine for marketing approval in Europe, where it will be marketed as Imvanex. Press release

> Medicago and Mitsubishi Tanabe have signed a $33 million deal to develop at least three new vaccines, including a rotavirus vaccine. Press release

> Nuron Biotech has licensed in rights to Akshaya Bio's Chimigen multi-antigen hepatitis B vaccines, as well as an option to license prophylactic and therapeutic products for the hepatitis C virus. Press release

> iBio, a biopharma company that develops plant-based products, has received a patent for its technology to enhance the effectiveness of vaccines. Article

> Novavax's ($NVAX) flu shot has begun Phase II clinical trials, with data expected in the third quarter. Press release

> A Cuban hepatitis B vaccine is in clinical trials, which are "almost finished." Article

> The University of Cincinnati is carrying out a Phase II trial of an ovarian cancer vaccine. Press release

> Researchers in Ireland are conducting the country's first ever malaria vaccine clinical trial, and results are expected later this year. Press release

> Intercell ($ICLL) has begun the second part of its Phase I clostridium vaccine trial. Press release

> Panacea Biotec has withdrawn its oral polio vaccine from the WHO's list of pre-qualified vaccines because of manufacturing issues. Article

And Finally… The current anti-smoking shots in development are not likely to be cost-effective, according to an Australian study. Story

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.